Press Releases

05-18-2022	Pliant Therapeutics Announces Presentations at 2022 American Thoracic Society International Conference
05-11-2022	Pliant Therapeutics to Participate in Upcoming Investor Conferences
05-09-2022	Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results
05-05-2022	Pliant Therapeutics Enters into $100 million Loan Facility Agreement with Oxford Finance to Support Ongoing Development of PLN-74809
05-03-2022	Pliant Therapeutics Receives FDA Fast Track Designation for PLN-74809 for the Treatment of Idiopathic Pulmonary Fibrosis
05-02-2022	Pliant Therapeutics Announces Multiple Presentations at the 2022 American Thoracic Society International Conference
04-05-2022	Pliant Therapeutics to Participate in Needham Healthcare Conference
02-28-2022	Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
02-28-2022	Pliant Therapeutics Announces Positive Data from Expanded Phase 1b BAL Trial of PLN-74809 Demonstrated Suppression of TGF-β Signaling in Healthy Volunteers
02-24-2022	Pliant Therapeutics Announces Positive DSMB Safety Review and Commencement of Enrollment of Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis

Investors & Media